$ETST Earth Science Tech, Inc. Signs Contract with Absolu to Advance Phase-2 Rollout on MSN-2 Medical Device
GlobeNewswire•August 3, 2017
Hollywood, FL, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid, nutraceutical, pharmaceutical, and medical device research and development, signs agreement with Absolu Communications (www.absolu.ca), one of Canada’s most prestigious integrated web and communications companies, to handle the branding and rollout of ETST’s much-anticipated MSN-2 medical device (www.msn-2.com).
Under the terms of the contract, Absolu will immediately begin work on developing the branding of the new MSN-2 medical device; including the brand name, visual identity (logo, packaging, artwork), and marketing language around the new product. In Phase Two of the contract, Absolu will develop a secure transactional website, which will allow ETST to sell the device via the web to customers anywhere in the world. The additional security concern will help ensure customers’ identities and personal information are protected. In Phase Three, the agency will deliver a Communications and Marketing Action Plan for the rollout of the new device. They will also manage the launch of the MSN-2, and the accompanying publicity.
“We are very proud to be working with Absolu on the pre-launch and launch of the MSN-2, and we hope to continue our relationship as we roll out our new nutrition and nutraceutical products in the coming year,” said Chief Executive Officer and Chief Scientific Officer Michel Aubé, PhD.
The MSN-2 medical device is a new product, which will allow women to manage their own testing for Sexually Transmitted Diseases. Using MSN-2, women can collect their own cell sample in the privacy of their home and send it anonymously to a dedicated laboratory for testing. The MSN-2 is slated to launch during Q1 2018, and has been a key component of the company-wide women’s health initiatives.
ETST’s President, Director, and COO, Nickolas S. Tabraue concluded, “We expect to sign an agreement within three weeks for an exclusive distribution of a new medical devices manufacture by our future partner in two countries. This is an important step, as the release of our own MSN-2 medical device will be in the same timeline as this second medical device. We will have two medical devices ready to market overseas first, and in North America shortly after. This is an important step, as releasing our medical device in the North American markets will likely be delayed by several months, due to the complex nature of the regulatory environment in the US and Canada. We plan on updating our shareholders as further progress and development occurs.”
AI
